Across thousands of rare and genetic conditions, the epidemiological and market data that should guide research, funding and care decisions sits behind reports priced for large institutions. We're building a single, open platform that brings that intelligence to everyone working on rare disease — at a fraction of the cost.
Rare disease data exists — it's just scattered, expensive, and built for buyers with enterprise budgets.
Prevalence figures, treatment landscapes and patient population estimates are spread across registries, journals and proprietary databases that rarely talk to each other.
A single market report from a traditional research firm can cost several thousand euros — out of reach for independent researchers, patient organizations and early-stage teams.
When only well-funded players can act on the data, promising work from smaller teams and patient-led initiatives loses the visibility it needs to attract funding and attention.
DATAFY brings health and market intelligence on rare diseases into a single, searchable platform — built for people who need answers, not another PDF. DATAFY democratizes access to critical insights, allowing anyone to instantly grasp future case numbers and market size for specific rare diseases.
Better access doesn't just save time — it changes what becomes possible.
Landscape reviews and feasibility checks that used to take weeks of manual digging can take hours, leaving more time for the actual science.
Underserved and ultra-rare conditions get overlooked when the evidence behind them is invisible. Better data means better odds of trials, funding and care pathways.
When evidence isn't gated by budget, more founders, academic groups and patient organizations can move from idea to action.
The platform isn't live yet — and we want to build it with the people who'll actually use it. Tell us what data you need, how you currently work around its absence, and what would make this indispensable for your work.
Join Early AccessTakes about 1 minute · no payment, no commitment
Anyone who needs reliable evidence on rare diseases without an enterprise budget: academic and clinical researchers, biotech and pharma teams, patient organizations, healthcare investors and market analysts.
We're in active development. Early access participants will be the first to try the platform and will directly shape what we ship first — there's no fixed launch date yet, and we'd rather get it right than rush it.
Traditional reports are static, expensive, and usually cover one disease or narrow market at a time. DATAFY gives continuously updated, queryable access across the rare disease landscape — so you pay for ongoing access, not a one-off PDF.